The synthetic molecule CB-103 blocks the functional interaction between RBP-J and NICD, showing antitumor activity against T-ALL cells, TNBC xenografts in mouse models [195], and T-ALL in clinical studies [196]. This evidence concerns the gene RBPJ and acute lymphoblastic leukemia.